Scalper1 News
When big biotechs Amgen and Regeneron launched their new cholesterol drugs Repatha and Praluent this summer, Wall Street uniformly predicted blockbuster sales, though they debated just how big. After all, one in seven adult Americans have high cholesterol, and Pfizer’s (PFE) Lipitor was the biggest-selling drug in the world before it went off patent in 2011 and got generic rivals. Yet the statins — the drug class to which Lipitor belongs — aren’t Scalper1 News
Scalper1 News